Citations Report
Clinical Schizophrenia & Related Psychoses : Citations & Metrics Report
Articles published in Clinical Schizophrenia & Related Psychoses have been cited by esteemed scholars and scientists all around the world. Clinical Schizophrenia & Related Psychoses has got h-index 41, which means every article in Clinical Schizophrenia & Related Psychoses has got 41 average citations.
Following are the list of articles that have cited the articles published in Clinical Schizophrenia & Related Psychoses.
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
Year wise published articles |
105 | 141 | 28 | 8 | 28 |
Year wise citations received |
543 | 553 | 590 | 563 | 587 |
| Journal total citations count | 6601 |
| Journal Impact Factor | 6.49 |
| Journal 5 years Impact Factor | 12.17 |
| Journal CiteScore | 11.19 |
| Journal h-index | 41 |
| Journal h-index since 2016 | 26 |
Prins, Bram P., Ali Abbasi, Anson Wong, Ahmad Vaez, Ilja Nolte, Nora Franceschini, Philip E. Stuart et al. "Investigating the causal relationship of C-reactive protein with 32 complex somatic and psychiatric outcomes: a large-scale cross-consortium Mendelian randomization study." PLoS medicine 13, no. 6 (2016): e1001976. |
|
Cho, Myeongju, Tae Young Lee, Yoo Bin Kwak, Youngwoo Brian Yoon, Minah Kim, and Jun Soo Kwon. "Adjunctive use of anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials." Australian & New Zealand Journal of Psychiatry 53, no. 8 (2019): 742-759. |
|
Galletly, Cherrie. "Role of cognitive enhancement in schizophrenia." Neuroscience and Neuroeconomics 3 (2014): 75-85. |
|
Stojanovic, Alexander, Lourdes Martorell, Itziar Montalvo, Laura Ortega, Rosa Monseny, Elisabet Vilella, and Javier Labad. "Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms." Psychoneuroendocrinology 41 (2014): 23-32. |
|
Smith, Conor C., Terrell T. Gibbs, and David H. Farb. "Pregnenolone sulfate as a modulator of synaptic plasticity." Psychopharmacology 231, no. 17 (2014): 3537-3556. |
|
Henderson, David C., Brenda Vincenzi, Nicolas V. Andrea, Melissa Ulloa, and Paul M. Copeland. "Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses." The Lancet Psychiatry 2, no. 5 (2015): 452-464. |
|
Meltzer, Herbert Y., Masakuni Horiguchi, and Bill W. Massey. "The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment." Psychopharmacology 213, no. 2 (2011): 289-305. |
|
Vreeker, Annabel, Annet H. van Bergen, and René S. Kahn. "Cognitive enhancing agents in schizophrenia and bipolar disorder." European Neuropsychopharmacology 25, no. 7 (2015): 969-1002. |
|
Soria, Virginia, Alexandre González-Rodríguez, Elena Huerta-Ramos, Judith Usall, Jesús Cobo, Miquel Bioque, Juan David Barbero et al. "Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis." Psychoneuroendocrinology 93 (2018): 8-19. |
|
Nitta, Masahiro, Taishiro Kishimoto, Norbert Müller, Mark Weiser, Michael Davidson, John M. Kane, and Christoph U. Correll. "Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials." Schizophrenia bulletin 39, no. 6 (2013): 1230-1241. |
|
Carolus, Almut, Petia Popova, and Brigitte Rockstroh. "Kognitive Defizite bei Schizophren Erkrankten." Zeitschrift für Klinische Psychologie und Psychotherapie (2015). |
|
Wang, Chih-Chieh, Richard G. Held, Shiao-Chi Chang, Lingling Yang, Eric Delpire, Anirvan Ghosh, and Benjamin J. Hall. "A critical role for GluN2B-containing NMDA receptors in cortical development and function." Neuron 72, no. 5 (2011): 789-805. |
|
Carolus, Almut, Petia Popova, and Brigitte Rockstroh. "Kognitive Defizite bei Schizophren Erkrankten." Zeitschrift für Klinische Psychologie und Psychotherapie (2015). |
|
Marx, Christine E., Jimmy Lee, Mythily Subramaniam, Attilio Rapisarda, Dianne CT Bautista, Edwin Chan, Jason D. Kilts et al. "Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia." Psychopharmacology 231, no. 17 (2014): 3647-3662. |
|
Wilkinson, Charles W., Kathleen F. Pagulayan, Eric C. Petrie, Cynthia L. Mayer, Elizabeth A. Colasurdo, Jane B. Shofer, Kim L. Hart, David Hoff, Matthew A. Tarabochia, and Elaine R. Peskind. "High prevalence of chronic pituitary and target-organ hormone abnormalities after blast-related mild traumatic brain injury." Frontiers in neurology 3 (2012): 11. |
|
Miyauchi, Tomoya. "Long-term improvement of aggression in a patient with schizophrenia using allopurinol as an adjuvant: a case report." Journal of clinical psychopharmacology 41, no. 2 (2021): 212-214. |
|
Vallée, Monique. "Neurosteroids and potential therapeutics: focus on pregnenolone." The Journal of steroid biochemistry and molecular biology 160 (2016): 78-87. |
|
Jones, Mackenzie T., and Philip D. Harvey. "Neurocognition and social cognition training as treatments for violence and aggression in people with severe mental illness." CNS spectrums 25, no. 2 (2020): 145-153. |
|
Fatemi, S. Hossein, and Timothy D. Folsom. "GABA receptor subunit distribution and FMRP–mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism." Schizophrenia research 167, no. 1-3 (2015): 42-56. |
|
Wang, Chih-Chieh, Richard G. Held, Shiao-Chi Chang, Lingling Yang, Eric Delpire, Anirvan Ghosh, and Benjamin J. Hall. "A critical role for GluN2B-containing NMDA receptors in cortical development and function." Neuron 72, no. 5 (2011): 789-805. |
|